Skip to main content

Table 2 Changes of main parameters during Paricalcitol (PCT) in the whole cohort (n = 48) and three months after withdrawal (n = 42)

From: Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study

 

Basal

Month 3

Month 6

PCT withdrawal

SBP/DBP (mmHg)

143 ± 22/78 ± 11

137 ± 15/78 ± 10

138 ± 17/79 ± 10

134 ± 16/77 ± 9

eGFR (mL/min/1.73 m2)

29.7 ± 14.5

27.3 ± 15.5

27.5 ± 16.2

26.9 ± 15.3

Serum potassium (mmol/L)

4.6 ± 0.7

4.8 ± 0.7

4.8 ± 0.6

4.7 ± 0.6

PTH (pg/mL)

201 (92–273)

140 (64–226)*

83 (50–189)*

111 (74–184)*

ALP (IU/L)

155 ± 96

148 ± 86

143 ± 93

135 ± 95

Serum Calcium (mg/dL)

9.3 ± 0.6

9.3 ± 0.5

9.4 ± 0.4

9.3 ± 0.6

Serum Phosphate (mg/dL)

3.9 ± 0.7

3.9 ± 0.8

3.9 ± 0.7

3.9 ± 0.7

Proteinuria (g/24 h)

1.23 (1.00-1.51)

0.85 (0.59-1.21)*

0.61 (0.40-0.93)*

1.12 (0.86-1.44)

UNaV (mmol/24 h)

161 ± 63

144 ± 55

149 ± 65

157 ± 66

  1. Data are mean ± SD or median and interquartile range (PTH) or geometric mean and 95% confidence interval (proteinuria). SBP/DBP, systolic/diastolic blood pressure; eGFR, 4-variable MDRD estimated GFR; ALP, Alkaline Phosphatase; UNaV, 24 h urinary Na excretion. *P < 0.05 vs basal.